Cargando…
Endogenous secretory leukocyte protease inhibitor inhibits microbial‐induced monocyte activation
In the intestine, epithelial factors condition incoming immune cells including monocytes to adapt their threshold of activation and prevent undesired inflammation. Colonic epithelial cells express Secretory Leukocyte Protease Inhibitor (SLPI), an inhibitor of NF kappa light chain enhancer of activat...
Autores principales: | Nugteren, Sandrine, Simons‐Oosterhuis, Ytje, Menckeberg, Celia L., Hulleman‐van Haaften, Danielle H., Lindenbergh‐Kortleve, Dicky J., Samsom, Janneke N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107746/ https://www.ncbi.nlm.nih.gov/pubmed/36480463 http://dx.doi.org/10.1002/eji.202249964 |
Ejemplares similares
-
Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis
por: Nugteren, Sandrine, et al.
Publicado: (2020) -
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence
por: Nugteren, Sandrine, et al.
Publicado: (2022) -
Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity
por: Kalogeropulou, Alexia F., et al.
Publicado: (2020) -
The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity
por: McGarry, Niamh, et al.
Publicado: (2015) -
Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage
por: Aparicio-Domingo, Patricia, et al.
Publicado: (2015)